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Abstract
Background: The aim of this study was to assess actual management of heart failure (HF)
in Poland, both in outpatient clinics and hospitals.
Methods and results: The survey was undertaken between April 21 2005 and December
31 2005 in 796 outpatient departments and 258 internal medicine and cardiology hospital
wards chosen at random. In total 3980 HF outpatients and 1294 inpatients were included.
Trained nurses performed the questionnaire-based assessment of diagnostic procedures and
pharmacotherapy. Heart failure was diagnosed among general practitioners’ (GPs) outpa-
tients most frequently, basing on symptoms (64.0%), ECG (47.0%) and chest X-ray (29.9%),
while specialists based their diagnosis on symptoms (52.2%) and echocardiography (37.7%).
Most HF outpatients and hospital patients were treated with ACE-I (88.3% and 81%, respec-
tively), beta-blockers (68.3% vs. 84.7%) and diuretics (74.4% vs. 90.3%). Spironolactone
accounted for 48.3% vs. 56.3% of the patients, while digitalis glycosides 39.2% and 27.4%,
respectively. AT-1 blockers were used very rarely (3.5% vs. 2.5%).
Conclusions: GPs in Poland tend to diagnose HF on clinical grounds while specialists use
more diagnostic investigations. Specialists provide higher quality HF care than GPs, both in
outpatient clinics and hospitals. Significant progress in HF management has occurred in
Poland since previous studies. (Cardiol J 2007; 14: 552–560)
Key words: heart failure management
Editorial p. 521
553
Małgorzata Fedyk-Łukasik et al., Heart failure management in Poland
www.cardiologyjournal.org
Introduction
In Western Europe, heart failure (HF), con-
firmed in diagnostic tests or based on clinical
premises, affects 5% of the population [1]. Matters
of extreme importance include: the progressive
course of the disease [2, 3], the high prevalence of
rehospitalisation, and poor prognosis — worse than
in some cancers (five-year survival is noted in about
25% of HF cases) [4]. It is assumed that in Poland
about 800,000 to 1,000,000 people suffer from HF [5],
yet we must presume that this number will grow
— paradoxically, because of the development of
medicine and, consequently, prolonged human life.
Research carried out by Poznań medical centre
shows that patients with HF (usually 60–80 years
old) comprise 10–20% of general practitioners’
(GPs) patients [6].
Although diagnosis of HF usually takes place
in hospital, GPs and specialists in outpatient clinics
continue the treatment [7]. This is both a challenge
and a reason for Polish and European health servic-
es to improve medical care in this field [8–11].
The international research project IMPROVE-
MENT, also performed in Poland (1999–2000) among
GPs, has shown that the treatment of patients with
HF differs from the European Society of Cardiology
(ESC) guidelines [12], edited in 2001, both in diag-
nostics and pharmacological treatment [13]. For in-
stance, echocardiography, along with clinical state-
ments, is the basis of HF diagnosis, yet the Polish part
of the IMRPOVEMENT research project showed that
only 18% of GPs named echocardiography as a nec-
essary diagnostic examination [14]. In hospitals, this
examination was done in 66% of HF cases; it occurred
slightly more frequently in academic centres (68%).
The basic medications used in HF patients in GPs’
practices were ACE inhibitors and beta-blockers, in
65% and 34% of cases, respectively.
The present study was performed as part of the
National Cardiovascular Disease Prevention and
Treatment Program — POLKARD edition 2003–
–2005 (POLKARD), to evaluate diagnostics and
therapy of HF in Poland among outpatient and hos-
pital clinics, referring to the level of specialization
and their position in the health service structure.
Methods
The methodology was described previously in
detail [15]. The survey method used was based on
three questionnaires to be filled out by doctors,
patients and hospital managers, respectively. The
data were obtained from medical files on HF
patients’ medical history, and diagnostic and therapeu-
tic procedures, and was complemented with demo-
graphic data and patients’ reports on the availabili-
ty and quality of medical care, taken by 87 trained
nurses. We also asked managers of all analyzed
centres about the staff, procedures and medical
equipment used there.
The multi-stage procedure of choosing the
health centres to be investigated was designed to
obtain a representative sample both for medical
units and HF patients visiting outpatient clinics or
discharged from hospitals. Randomization among
hospitals was based on the governmental registra-
tion list (posted 17 March 2005) and a representa-
tive number of 260 hospitals (of which one refused
to take part in the research) with internal medicine
or cardiology departments were chosen. Conse-
quently, the last five patients discharged with HF
diagnosis were identified and their medical records
were analyzed.
Recruitment of outpatient clinics was conduct-
ed in a similar way: 400 units were found by random
choice from the governmental list, and the last five
patients with diagnosed HF formed the research
patient sample. The choice of 400 specialists work-
ing in outpatient departments was not random; they
were indicated by the GPs included in the study
as their consultants. All information from the last
365 days of case histories came from 396 specialists.
All included patients had HF diagnosed accord-
ing to symptoms or laboratory examinations or im-
aging methods or pharmacotherapy response, and
confirmation in their medical files (upon discharge
or in case history). The only excluding criterion was
an active neoplastic disease. All procedures of data
gathering were subject to Polish regulations.
Results
The obtained data are presented as follows: HF
patient characteristics, diagnostic procedures, ans
treatment and prognosis in HF. Each category con-
cerned hospital units and outpatient clinics, sepa-
rately. We took under consideration differences in
demographic data, village or city populations, posi-
tion in health care structure, and the availability of
therapeutic procedures.
Patient population
In total, 3980 outpatients with HF were recruit-
ed, including 2000 patients of GPs, 1970 patients
of specialist care and 10 patients of an undefined
level of care. The majority were male (53%), espe-
cially at the specialist care level (64%), over 70 years
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of age and in NYHA classes II and III. Additionally,
1294 patients discharged from hospitals with HF
were enrolled. Most of them were males (53.1%),
predominantly over 70 years of age and in NYHA
classes III and IV. NYHA class increased with age:
most of NYHA class I concerned patients under 50, and
NYHA classes III–IV were diagnosed in patients over
80 years of age. Table 1 shows the study population.
Diagnosis
As echocardiography is a recommended meth-
od in HF diagnosis, its usage in hospitals and out-
patient clinics was analyzed, considering patients’
age, NYHA class and community size (Table 2).
Usage of echocardiography depended on age and in-
creased with community size and the level of spe-
cialization of the medical unit, both in outpatient clin-
ics and hospital wards. Specialists diagnosed HF with
echocardiography more frequently, with no differenc-
es among NYHA classes and city populations in out-
patient clinics. Figure 1 shows the basis of HF diag-
nosis in outpatient clinics and hospital units.
Laboratory tests
We reviewed laboratory tests peformed on HF
outpatients during the last year, including BNP and
NT-proBNP. GPs and specialists made tests with
similar frequency. The frequency of laboratory tests
made during the last hospitalization revealed no
significant differences between hospital units
either, excluding BNP or NT-proBNP tests, which
were used a few times more often in university clin-
ics than in other medicine units. Almost all hospi-
talized patients underwent ECG tests; most of them
chest X-ray and echocardiography. The differenc-
es between the medical units are shown in Table 3.
Treatment
The analysis of pharmacotherapy used in HF
outpatients showed that the majority of them were
treated with ACE-I, beta-blockers and diuretics.
Spironolactone and digitalis were less common
(< 50%). AT-1 blockers were rarely used in outpa-
tient clinics (3.7%) or hospital units (2.2%). Differ-
ences in drug intake were revealed among the var-
ious age groups of HF outpatients (Fig. 2). Older
patients were rarely given beta-blockers, with the
opposite trend in diuretics and digitalis. The phar-
macotherapy used in hospitals was not influenced
by the patients’ age, except for beta-blockers, which
were less frequently used in older patients (Fig. 3).
A similar trend was observed in spironolactone in-
take, but was not expressed so much. Digitalis was
used less often than other drugs at every age. There
was a significant difference between hospital and
outpatient prevalence of spironolactone, more
Table 1. Study population.
Health care level
Outpatient clinics Hospitals
GPs Specialists Internal medicine units Cardiology units
Males (%) 53.0*** 64.0 53.1*** 68.0
Age (mean ± SD) 68.8 ± 11.8 65.4 ± 11.5 71.4 ± 10.6 66.5 ± 12.2
Years (%)
£ 50 7.2*** 10.6 3.6*** 8.1
51–60 19.1*** 25.2 12.8*** 26.8
61–70 23.1** 26.7 23.9 21.5
71–80 34.5*** 29.4 39.5** 30.6
≥ 81 16.1*** 8.1 20.2*** 12.9
NYHA class (%)
I 4.0 4.3 0.6 1.0
II 46.9*** 55.2 19.4 18.9
III 43.9*** 36.0 51.8 48.8
IV 4.9 3.9 27.7 30.1
Coronary artery disease (%) 82.4*** 76.8 70.2* 75.7
Hypertension (%) 84.5*** 71.8 73.4* 67.2
Myocardial infarction (%) 35.1*** 46.8 29.6*** 49.9
Diabetes (%) 31.6*** 25.4 34.8 29.7
Atrial fibrillation (%) 39.4 36.6 45.8* 39.6
*p < 0.05, **p < 0.01, ***p < 0.001
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Table 2. Percentage of heart failure patients tested with echocardiography.
Outpatient clinics Hospitals
GPs Specialist care Internal Cardiology units
medicine units
Tests made# (No of patients) 879 1493 413 344
Test made## (% of patients) 44 76*** 48 82***
NYHA class (% of available)
I 47.4 67.9** 80.0 100***
II 43.9 74.4*** 51.8 83.1***
III 44.3 79.5*** 47.5 83.3***
IV 45.4 83.3*** 43.8 79.4***
Age (%)
£ 50 63.8 89.4*** 80.6 97.0*
51–60 55.3 83.2*** 61.3 81.3***
61–70 47.9 74.6*** 51.7 79.8***
71–80 37.6 71.1*** 47.1 82.0***
> 80 31.6^ 61.4*** 28.7^ 81.5***
Population (%)
Rural areas 42.6 – – –
Towns £ 30 000 46.6 73.7 37.9 82.1***
30 000–80 000 44.6 69.9 52.7 71.2**
80 000–400 000 49.0 86.4 61.1 79.8**
> 400 000 42.7 75.8 55.4 87.7***
Echocardiography not performed 56 24 52 18
No need/indication 4.1*** 2.0 2.3 –
Cost too high 1.8** 0.8 0.3 –
No availability 8.5*** 2.1 7.7*** 0.2
Non compliance of patient 1.7*** 0.2 0.3 –
Others 3.0*** 1.1 1.4* 0.2
Missing data 37.0 18.0 40.4 17.4
#Echocardiography made in previous 365 days or echocardiography made during last hospitalization, ##records available in questionnaire,
*p < 0.05; **p < 0.01; ***p < 0.001; ^p < 0.001 (the youngest group vs. the oldest group)
often given in hospitals. Table 4 gives the type of
agents prescribed at hospital discharge and in out-
patient clinic within the last 365 days for different
NYHA classes. ACE-I were the most commonly
prescribed drugs in NYHA classes I–III, while diu-
retics predominated in class IV. GPs used ACE-I
less in every NYHA class. They also used fewer
beta-blockers than specialists and hospital physi-
cians. Spironolactone accounted for 18.1 to 88.3%
of patients, increasing with higher NYHA class. The
rate of prescription of digitalis was similar among
NYHA classes and medical units, excluding NYHA IV
by GPs, in which digitalis was used more often
(61.9%). Results for NYHA I in both hospital groups
were not representative due to the small number
of patients (n = 5; n = 4).
Discussion
The Heart Failure POLKARD-2005 survey
was the largest survey on HF in Poland, having
Figure 1. Basis of heart failure diagnosis in outpatient
clinics and hospital units.
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screened 3980 patients of outpatient clinics (1980
patients in specialist care and 2000 in the care of
primary physicians) and 1294 patients discharged
from 259 internal medicine and cardiology wards
including 20 university hospitals. The purpose of
the survey was to provide credible data on HF man-
agement, to compare the data to European guide-
lines and to formulate a program of improvement.
Representative samples of physicians were invited
to participate in this study. This paper describes two
major areas of interest in HF management: diag-
nosis and treatment. Previous studies on HF epi-
demiology and management in Poland were made
within the IMPROVEMENT project (1999–2000).
Another multicentre retrospective study was per-
formed in 2003 by the Institute of Cardiology in
Warsaw involving 350 patients of cardiology units
and 450 patients of internal wards. A comparison of
Table 3. Laboratory tests made in heart failure patients.
Patients (%) Outpatient clinics# Hospital units##
GPs Specialists Internal medicine Cardiology
Blood cell count 88.2*** 77.1 99.7*** 97.9
ASPAT 65.1*** 59.2 62.6 71.1**
Glycemia 92.1*** 81.7 98.6 97.1
Na 77.4 80.4* 99.3* 97.9
K 80.7 83.9** 99.8 98.3
Creatinine 78.7 80.1 94.8 97.1*
BNP/NTproBNP 2.7 6.9*** 1.5 7.2***
Urine test 86.7*** 67.7 94.8*** 78.3
ECG 94.3 98.7*** 99.8 98.6
Chest X-ray 68.3*** 63.6 80.9*** 70.6
ECHO 44.0 75.8*** 48.0 82.0***
Coronarography 13.5 18.1*** 1.0 18.2***
Spirometry 23.4 11.8 6.3 6.9
ECG 24 25.2 42.4*** 12.1 28.9***
Exercise test 21.7 26.2*** 5.2 8.4*
#Tests made in previous 365 days, ##tests made during last hospitalization, *p < 0.05; **p < 0.01; ***p < 0.001
Figure 2. Percentage of patients taking pharmacothera-
py by age in outpatient clinics.
Figure 3. Percentage of patients taking pharmacothera-
py by age in hospitals.
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study populations showed great similarities (accord-
ing to age, gender and NYHA class) in spite of dif-
ferent methods of patient qualification [16]. The
mean age in the POLKARD study was 68.8 years
(66 in the Polish part of the IMPROVEMENT study
and 70 in Europe), with the majority being men
(58.5% vs. 55% and 55%, respectively). The most
numerous group was that of patients 71–80 years
of age, in every level of care; this was in accordance
with the prevalence of HF in the population [17].
The very small percentage (0.6–4.2%) of patients
with NYHA class I was as expected since those
patients were diagnosed with HF probably “by the
way” during a visit or hospitalization for another
reason. Patients with NYHA class II were primari-
ly from outpatient clinics (46.9% in primary care and
55.2% in specialists’ consulting rooms), whereas
NYHA class III were primarily from hospitals
(51.8% of patients discharged from internal medi-
cine units and 48.8% from cardiology units), with
a significant rate of NYHA class IV (27.2% and 31%).
This reflects the natural and progressive course of
this disorder, with  exacerbations more frequently
requiring hospitalization and a greater number of
deaths in higher NYHA classes. Most of the patients
suffered from concomitant disorders, featuring as
a cause of HF and having a key role in its progres-
sion and response to therapy. Coronary artery dis-
ease contributed prominently to HF in our study as
well. Its prevalence ranged from 70.2% to 82.4%
and was higher than in other clinical trials [18] prob-
ably due to the simple inclusion criteria and deep
insight into medical files. It was also more frequent
than in data from the Polish IMPROVEMENT study
(65%) [13] and comparable with data from the
EuroHeart Failure survey program (71%) [19]. The
IMPROVEMENT study showed hypertension
present in 47% of HF cases in Poland and in 58% of
the EuroHeart study; the POLKARD study re-
vealed that the frequency of hypertension diagnosed
among HF patients was higher (67.2–84.5%). Spe-
cialists, both in outpatient and hospital subgroups,
diagnosed it less frequently. Diabetes was the most
non-cardiovascular concomitant disease in our
study population (25.4–34.8%) and more frequent
than in the trials cited above. The cause of such
Table 4. Treatment by NYHA classes and medical units.
ACE-I (%) Beta-blockers (%) Diuretics (%) Spironolactone (%) Digitalis (%)
GPs
Total 81.0 68.3 74.5 48.3 32.3
NYHA I 73.4 61.5 45.6 29.1 16.5
NYHA II 81.9 71.2 68.7 40.7 24.7
NYHA III 81.0 67.3 81.7 55.7 38.5
NYHA IV 79.4 55.7 90.8 72.4 61.9
Specialists
Total 88.3** 86.0** 74.4 56.3** 27.4*
NYHA I 78.6 88.1 42.9 18.1 10.8
NYHA II 89.8 85.5 67.9 48.7 20.5
NYHA III 88.0 86.3 86.3 69.0 37.5
NYHA IV 84.4 87.0 92.2 88.3 49.4
Internal medicine units
Total 84.3 71.7 90.3 64.1 39.2
NYHA I (n = 5) 100.0 100.0 40.0 20.0 40.0
NYHA II 86.3 73.8 77.4 42.3 20.8
NYHA III 84.4 71.9 91.8 66.1 40.5
NYHA IV 81.7 69.6 97.5 77.5 49.2
Cardiology units
Total 87.4 84.7^^ 85.9^ 67.8 36.8
NYHA I (n = 4) 75.0 100.0 25.0 25.0 25.0
NYHA II 86.1 86.1 64.1 51.9 17.9
NYHA III 88.2 87.7 90.2 72.5 36.9
NYHA IV 88.1 78.6 96.0 73.0 48.4
Specialists vs. GPs: *p < 0.01; **p < 0.001; cardiology vs. internal units:  ^p < 0.01; ^^p < 0.001
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differences is not clear, as HF populations seemed
to be representative; however, some of them could
be dependent on the differing ways of recruitment.
Diagnosis
The mainstay of optimum HF management is
reliable and precise diagnosis relating to the crite-
ria for the definition of the disease. The guidelines
given by the European Society of Cardiology and
the American College of Cardiology/American
Heart Association state that the diagnosis of HF is
evidenced when there are typical signs and symp-
toms of HF and when myocardial dysfunction oc-
curs, confirmed by cardiac dysfunction in echocar-
diography at rest. If applicable, the diagnostic pro-
cedure can be completed with a clinical response
(positive) to treatment directed at HF. Surprising-
ly, only 64% of GPs and 52.2% of specialists in non-
hospital care reported symptoms as the basis of HF
diagnosis; it could be expected to be almost 100%.
Confirmation was not reliable either; they claimed
to make echocardiographic tests in 17.2% and
37.7% of their HF patients. This does not allow us
to challenge doctors’ diagnoses, but forces us to
compare their declared knowledge about HF and
their everyday practice. According to the
IMPROVEMENT data, 82% of HF patients in Po-
land receiving primary care had breathlessness,
82% — fatigue and 60% — ankle swelling. This
could suggest that GPs use their knowledge in prac-
tice but they do not relate observed symptoms to
precise definition of HF. The most common prima-
ry care outpatient clinics do not provide facilities
for specialist investigation, which results in rare use
of echocardiography in diagnostic processes. More-
over, IMPROVEMENT data showed that only 19%
of GPs in Poland usually ask for it. As a consequence
of delayed access to the most appropriate objective
test, namely echocardiography (only 69% of the
patients had ever had echocardiography performed),
physicians rely on alternatives to it such as ECG
or chest X-ray. Some of those tests were performed
for routine diagnostic purposes or for the purposes
of another disease. Our study showed a better, but
still unsatisfying, situation in hospitals, both gen-
eral and cardiological. There were recognized HF
symptoms in 82% of patients of internal medicine
units and 84.2% of patients in cardiology units, and
echocardiographic tests were performed in 48% and
82% of cases, respectively, during last hospitaliza-
tion. However, it should be kept in mind that a great
proportion of hospitalized patients were previous-
ly hospitalized with a full range of tests performed,
including echocardiography.
NYHA class had an impact on the frequency of
echocardiography usage and decreases in all sub-
groups but not in consulting rooms. Less often, the
use of echocardiography in older patients probably
depended on the HF diagnosis given earlier, before
the analyzed period. There was full access to
records of echocardiographic tests only in about
56% of outpatients who underwent it, and it was eas-
ier in specialists’ files (77%) than GPs’ files (34%).
The IMPROVEMENT data showed a greater fre-
quency of echocardiography used for HF manage-
ment than ours (on average 69% vs. 56%). As men-
tioned above, almost none of the primary care outpa-
tient clinics provided facilities for echocardiography,
as in all of Europe [20], and the results of these tests
for GPs were provided from specialists or hospitals.
Most of the patients of primary care were cured by
cardiologists too; some disturbances in information
flow, between levels of HF care, seem to be impor-
tant, as confirmed in our data (see: tests made vs.
records available). There was progress made in
echocardiography access, noted in Polish hospitals,
compared our to previous studies. In 2000–2001,
the EuroHeart data showed that 46% of admitted
HF patients underwent echocardiographic tests and
63% had available results. In 2003 Zieliński et al. [21]
revealed that 37.8% of HF patients in internal med-
icine units and 73.1% in specialist care wards un-
derwent echo tests, while our data showed 48% and
82%, respectively, at present.
Biochemical and laboratory tests were com-
monly performed, specifically in hospital units. BNP
and NT-proBNP tests were rarely used, with maxi-
mum frequency of 7.2% of hospital cardiology unit
patients. These tests were poorly available, both for
diagnostics and monitoring of HF. Other tests in our
study were made at similar frequency correspond-
ing to the EuroHeart study subgroups of patients
(ECG, Chest X-ray, exercise test, coronary angio-
gram and pulmonary function).
Pharmacotherapy
According to guidelines, all HF patients with-
out contraindications should be treated with ACE-I.
Our results show a widespread perception of the
effectiveness of this group of drugs. Only 11.7–19%
of HF patients did not take ACE-I, probably due to
side effects or contraindications. In comparison to
the IMPROVEMENT results and statistical data
from the Department of Hygiene and Main Statis-
tical Office in Poland [22] it should be stated that
increased usage of ACE-I in HF from about 65% by
primary care physicians in 1995–2000, up to 81%
and 88.3% by cardiologists in consulting rooms,
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at present. A similar trend was observed in hospital
usage of ACE-I (from about 70% in the EuroHeart
study in 2000–2001 and 82.6–87.8% in the Institute
of Cardiology survey, up to 84.3–87.4% at present).
The higher level of specialization of the physician
went together with more frequently prescribed
ACE-I, totally and in every NYHA class, in both
outpatient clinics and hospital wards. It could be
dependent on more precise HF monitoring and
greater experience and knowledge. Age was not
a limitation in ACE-I treatment in our study, with
a similar percentage of HF patients by age, given
those drugs.
The CHARM Programme (Candesartan in
Heart Failure — Assessment of Reduction in Mor-
tality and Morbidity) proved the efficacy of angi-
otensin-II antagonists in HF treatment, not only as
an alternative for patients intolerant to ACE-I but
also in a broad spectrum of HF patients whose
medication was based on clinical diagnosis only,
including those with and without preserved left
ventricular function [23]. The rare cases of prescrip-
tion of those drugs depended on the doctor’s belief
in narrow indications, limited to intolerance of ACE-I
and the price (lack of reimbursement).
Several randomized clinical trials have document-
ed the principal effect of beta-receptor blockade in
reducing morbidity and mortality among patients with
HF, hypertension and coronary artery disease.
Our data showed a significant increase in the
usage of b-blockers in HF compared to the IM-
PROVEMENT study (68.3–86% vs. 34%), the Eu-
roHeart study (71.7–84.7% vs. 46%) and Institute
of Cardiology results (71.7–84.7% vs. 50.4–61.7%).
The higher level of specialization of the physician
went together with the more frequently prescribed
beta-blockers, as in ACE-I drugs, in both outpatient
clinics and hospital wards. The differences between
GPs and specialists increased with higher NYHA
class, but in hospital wards those differences were
smaller. In older patients, beta-blockers were less
commonly used with barely significant differences
among hospital and outpatient units.
The ESC guidelines recommend diuretics for
the treatment of fluid overload in HF, although
there is no evidence that they reduce mortality.
Some experts suggest that non-potassium-sparing
diuretics (nPSDs) may cause even more rapid pro-
gression of HF [24, 25] and should be prescribed
alongside spironolactone or other potassium-spar-
ing diuretics (PSDs). Use of diuretics follows the
natural progression of HF, and this pattern was re-
flected in our results, with the most frequent pre-
scription in NYHA class IV. As diuretics are the
group of drugs traditionally used in HF and hyper-
tension as a comorbidity, they could be over repre-
sented, especially in NYHA class I. There is evi-
dence to support the use of spironolactone in HF
patients with advanced symptoms in NYHA class-
es III and IV. Our data showed that spironolactone,
as a representative of aldosterone antagonists and
PSDs, was used much less than diuretics (nPSDs),
with range 48.3–67.8%, more often prescribed by
specialists than GPs and more often in hospitals. It
increased in comparison to the EuroHeart results
when slightly more than 20% of the European HF
patient population received spironolactone. We
hope it also reflected a better acceptance of the
conclusions of clinical trials and the ESC guidelines.
Digitalis glycosides have been used to treat HF
for more than 200 years, with periods of fascination
and rejection. In our study physicians of primary
care used digitalis glycosides slightly more often
than cardiologists, in their consulting rooms, and
this regularity concerns patients in every NYHA
class, particularly in NYHA class IV. A similar cor-
relation was observed between internists and car-
diologists in hospital units. Outpatients were more
likely to receive digitalis when older, while hospi-
talized patients were prescribed digitalis regardless
of age. This suggests either different populations were
included or the guidelines were  not followed equally.
On the other hand, the prevalence of digitalis usage
in HF in Poland has not changed significantly since
the IMPROVEMENT and EuroHeart studies and
have been close to the European average rate.
Conclusions
GPs and cardiologists differ in their diagnosis
and management of HF. While GPs tend to diagnose
more on clinical grounds, cardiologists use more
diagnostic investigations, also due to the different
patient populations treated. Cardiologists may pro-
vide higher quality HF care than GPs, both in out-
patient clinics and hospitals. Improvement in HF
management is possible by better organization and
by streamlining information flow between levels of
care, to make diagnostic procedures and medication
more effective. However, significant progress in HF
management has taken place in Poland since pre-
vious studies.
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